• BRCAness and Olaparib Sensitivity in Mesothelioma

  2026-09-20

  Borchert et al. linked homologous recombination repair gene-expression patterns with olaparib response in malignant pleural mesothelioma, with particular sensitivity observed in BAP1-mutated models. The study integrates cell-line treatment experiments with profiling of 91 clinical samples, providing a framework for biomarker-guided PARP-inhibitor research while highlighting the need for validation beyond in vitro systems.

• (-)-Blebbistatin for Cardiac Mechanics & Cell Assays

  2026-09-19

  (-)-Blebbistatin is a reversible, cell-permeable non-muscle myosin II inhibitor for separating actomyosin-dependent mechanics from electrical signaling, adhesion, migration, and contractility. Used alongside HCN4 temperature-response experiments, it helps distinguish changes in pacemaker excitability from changes in force generation without directly targeting HCN channels.

• HyperPFU™ high-fidelity DNA polymerase Guide

  2026-09-18

  HyperPFU™ high-fidelity DNA polymerase is intended for accurate PCR amplification of long, GC-rich, inhibitor-affected, or otherwise difficult DNA templates. It is appropriate for blunt-ended products used in cloning and sequencing, but not for workflows that require 3′-A overhangs or polymerase-generated sticky ends.

• Caspase-3/NDUFS1 Axis in Trichothecene ROS

  2026-09-18

  This preprint identifies a mechanistic link between caspase-3 activation, cleavage of mitochondrial complex I subunit NDUFS1, and reactive oxygen species accumulation during DON- and T-2 toxin-induced liver injury. It also implicates ER-localized ERO1α as a parallel oxidative source, suggesting that mitochondrial and ER redox stress reinforce one another.

• Liraglutide and the Brain–Kidney AVP Axis

  2026-09-17

  Greenwood and colleagues combine a human before-and-after study with rat pituitary proteomics, phosphoproteomics, an AVP secretion reporter assay, and renal signaling analysis to connect liraglutide with reduced vasopressin release. The work identifies time- and sex-dependent synaptic phosphorylation changes and downstream aquaporin 2 regulation, providing a mechanistic framework for the fluid, renal, and cardiovascular effects of GLP-1 receptor agonists.

• SGI-1027: DNA Methyltransferase Inhibitor Workflows

  2026-09-17

  SGI-1027 supports mechanistic DNA methylation inhibition studies that connect DNMT activity with tumor suppressor gene reactivation and cancer-cell phenotypes. This workflow-focused guide shows how to separate cytostatic effects from cell killing, manage compound handling, and build stronger methylation-validation assays.

• Golgi-Tracker Green for Reliable Live-Cell Assays

  2026-09-16

  Learn how Golgi-Tracker Green, SKU B8813, supports reproducible live-cell Golgi apparatus imaging alongside viability, proliferation, and cytotoxicity assays. This scenario-driven guide covers probe compatibility, solvent handling, optimization, interpretation, and practical product-selection criteria.

• Midecamycin: From Ribosome Target to Translation Strategy

  2026-09-16

  Midecamycin is more than a Gram-positive screening antibiotic: its ribosomal mechanism, glycosylation-sensitive structure, and historical macrolide comparisons support a disciplined translational strategy for resistance, assay design, and microbiology research.

• PFHxS Hepatotoxicity and PPAR Signaling in Zebrafish

  2026-09-15

  This study combines transcriptomics, liver pathology, biochemical measurements, and mechanistic intervention to show that environmentally relevant PFHxS exposure disrupts liver development and function in larval zebrafish through PPAR-related signaling. Its paired pharmacological antagonist and PPAR morpholino experiments provide a useful framework for distinguishing pathway association from causal involvement in aquatic toxicology and related metabolic research.

• BCECF for Extracellular pH Assays

  2026-09-15

  BCECF enables quantitative, ratiometric measurement of extracellular and accessible-compartment pH, making it useful for ion transport, metabolic acidification, and microenvironment studies. This guide translates the ozone–macrophage efferocytosis findings into a practical pH-monitoring workflow while clearly separating established evidence from exploratory assay extensions.

• HyperScript RT SuperMix for qPCR in Exosomal miRNA

  2026-09-14

  HyperScript RT SuperMix for qPCR supports a carefully controlled two-step workflow for low-input exosomal RNA. This article explains how reverse-transcription design can strengthen miR-17-5p–Bcl11b gene expression analysis in sepsis research while preserving assay-specific validation.

• TMB in Peptide ELISA: From Color to Decision

  2026-09-14

  TMB and 3,3′,5,5′-Tetramethylbenzidine transform HRP-linked antibody binding into a measurable color signal. This article explains how TMB chemistry can strengthen Plasmodium vivax epitope screening while clarifying assay controls, interpretation, and limitations.

• PNU 74654: Reading Wnt Pathway Biology

  2026-09-13

  PNU 74654 is a Wnt signaling pathway inhibitor for dissecting β-catenin-dependent cell states. This guide connects its assay use to the WNT5a/GSK3/β-catenin control of muscle progenitor fate while clarifying what the evidence does—and does not—support.

• Targeted CRISPRi of Fabp4 Reverses Obesity Phenotypes

  2026-09-11

  The reference study developed a nonviral, adipocyte-targeted CRISPR interference platform that silences Fabp4 in white adipocytes. In obese mice, this tissue-selective intervention reduced obesity-associated inflammation and hepatic steatosis while improving insulin resistance, supporting targeted gene repression as a strategy for metabolic disorder research.

• Spatial Transcriptomics of Cortical Lewy Pathology

  2026-09-11

  Goralski et al. used pathology-guided spatial transcriptomics to identify cortical neuron classes that are selectively vulnerable to Lewy pathology and to define a conserved Lewy-associated molecular dysfunction from aggregates (LAMDA) signature. The study links cortical α-synuclein inclusions with disrupted synaptic, mitochondrial, proteasomal, endo-lysosomal, and cytoskeletal programs, while providing a framework for comparing human disease tissue with an α-synucleinopathy mouse model.

8536 records 1/570 page Next 12345 下5页 Last page